SINGAPORE and SEOUL, SOUTH KOREA; December 20, 2012 – To enhance its bioanalytical service offerings in Asia, Quintiles today announced an exclusive partnership with BioCore Co., Ltd., a leading Seoul-based bioanalytical contract research organization (CRO). Under the agreement, BioCore will provide its services to Quintiles exclusively for a two-year period.
“Gathering high-quality bioanalytical data early in development is crucial to biopharma companies making informed decisions that increase their probability of success in expensive later-stage trials,” said Jenny Zhang, vice president and general manager of Asia Laboratories, Quintiles. “This partnership with BioCore is part of our plan to add local capabilities as needed to augment Quintiles’ GLP (Good Laboratory Practice) bioanalytics lab and CAP (College of American Pathologists)-accredited network of central labs. In this way we put our customers’ needs first, and can work locally, regionally or globally as circumstances require.”
Quintiles’ growing global bioanalytical capabilities began with its acquisition of Advion BioServices in 2011. This group, now called Advion Bioanalytical Labs, a Quintiles company, will continue to serve Quintiles’ global markets while BioCore is available as an option for customers who desire a local bioanalytical lab in Asia.
BioCore President and Chief Executive Officer Hyung Sik Choie said: “This partnership expands BioCore’s bioanalysis and bioequivalence studies beyond Korea to other Asian countries. Our vision is to become more global; this alliance advances our efforts to achieve that vision.”
BioCore is South Korea’s largest provider of bioanalytical liquid chromatography-tandem mass spectrometry (LC/MS/MS) services. BioCore was South Korea’s first GLP-complaint centralized bioanalytical CRO (2005) and first to be certified by the Korea Food and Drug Administration as a Bioequivalence Testing Institution (2008).
Quintiles is the leading provider of biopharmaceutical services in Asia Pacific, with more than 6,000 employees in 14 countries, including wholly owned CAP-accredited central labs in India, China, Singapore and Japan. All Quintiles laboratories operate with uniform instrumentation and standard operating procedures, delivering high quality, harmonized data.
Quintiles is the world’s leading provider of biopharmaceutical services. With a network of more than 27,000 professionals working in more than 80 countries, we have helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes.
Jessie Lee, Media Relations (Jessie.email@example.com)
Greg Connors, Investor Relations (firstname.lastname@example.org)